A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG) (BELONG)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00626197 |
|
Recruitment Status :
Completed
First Posted : February 29, 2008
Last Update Posted : May 10, 2017
|
Sponsor:
Genentech, Inc.
Collaborator:
Roche Pharma AG
Information provided by (Responsible Party):
Genentech, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a Phase III, randomized, double-blind, placebo-controlled, multicentre, parallel-group study designed to evaluate the efficacy and safety of ocrelizumab added to SOC (corticosteroid plus one of two immunosuppressant regimens) compared with placebo added to SOC in patients with WHO or ISN Class III or IV lupus nephritis.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Lupus Nephritis Systemic Lupus Erythematosus | Drug: corticosteroids Drug: cyclophosphamide Drug: mycophenolate mofetil Drug: ocrelizumab Drug: placebo | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 381 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With WHO or ISN Class III or IV Nephritis Due to Systemic Lupus Erythematosus |
| Actual Study Start Date : | February 2008 |
| Actual Primary Completion Date : | October 2009 |
| Actual Study Completion Date : | October 2013 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Systemic lupus erythematosus
MedlinePlus related topics:
Lupus
Drug Information available for:
Ocrelizumab
| Arm | Intervention/treatment |
|---|---|
| Experimental: 1 |
Drug: corticosteroids
Intravenous and oral repeating dose Drug: cyclophosphamide Intravenous repeating dose Drug: mycophenolate mofetil oral repeating dose Drug: ocrelizumab Intravenous repeating dose |
| Placebo Comparator: 2 |
Drug: corticosteroids
Intravenous and oral repeating dose Drug: cyclophosphamide Intravenous repeating dose Drug: mycophenolate mofetil oral repeating dose Drug: placebo Intravenous repeating dose |
Primary Outcome Measures :
- Patients who achieve a complete renal response (CRR) [ Time Frame: Week 48 ]
- Patients who achieve a partial renal response (PRR) [ Time Frame: Week 48 ]
Secondary Outcome Measures :
- Proportion of patients who achieve a renal response, major clinical response, or partial clinical response [ Time Frame: Weeks 48, 72, and 96 ]
- Proportion of patients who achieve a reduction from baseline in SLEDAI 2K score, no worsening in physician's global assessment, no new BILAG A organ domain score, and no more than 1 new BILAG B organ domain score [ Time Frame: Week 48 ]
- Change in SF-36 subscale FACTIT-Fatigue assessment, change from baseline in pain quality, and impact of pain on daily function [ Time Frame: Week 48 ]
- Proportion of patients who achieve a CRR or PRR and who have received a daily dose of corticosteroids from Week 24 and average corticosteroid burden [ Time Frame: Week 48 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 16 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age 16 years or above at the time of the screening
- Ability and willingness to provide written informed consent and to comply with the schedule of protocol requirements
- Diagnosis of SLE
- Active lupus nephritis
Exclusion Criteria:
- Currently active retinitis, poorly controlled seizure disorder, acute confusional state, myelitis, stroke or stroke syndrome, cerebellar ataxia, or dementia
- Severe renal impairment
- Lack of peripheral venous access
- Pregnancy or breast feeding mothers
- History of severe allergic or anaphylactic reactions to humanized, chimeric or murine monoclonal antibodies or i.v. immunoglobulin
- Known severe chronic pulmonary disease
- Evidence of significant uncontrolled concomitant diseases in any organ system not related to SLE, which, in the investigator's opinion, would preclude patient participation
- Concomitant condition which has required treatment with systemic corticosteroid (excluding topical or inhaled steroids) prior to screening
- Known HIV or chronic active Hepatitis B or chronic active Hepatitis C infection
- Known active infection of any kind prior to Day 1
- History of serious recurrent or chronic infection
- History of cancer, including solid tumors, hematological malignancies and carcinoma in situ (except basal cell carcinoma of the skin that has been excised and cured).
- History of alcohol or drug abuse prior to screening
- Major surgery prior to screening, excluding diagnostic surgery
- Previous treatment with CAMPATH-1H
- Previous treatment with a BAFF directed treatment (e.g. anti-BLyS) prior to screening
- Previous treatment with a B-cell targeted therapy other than one directed at BAFF (e.g. anti-CD20, anti-CD22)
- Treatment with any investigational agent prior to screening
- Receipt of any live vaccines prior to Day 1
- Intolerance or contraindication to oral or i.v. corticosteroids
- Positive hepatitis BsAg or hepatitis C serology. Patients who are HBsAg negative but HBcAb positive may be enrolled with a negative DNA test
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00626197
Sponsors and Collaborators
Genentech, Inc.
Roche Pharma AG
Investigators
| Study Director: | Clinical Trials | Hoffmann-La Roche |
| Responsible Party: | Genentech, Inc. |
| ClinicalTrials.gov Identifier: | NCT00626197 History of Changes |
| Other Study ID Numbers: |
ACT4072g WA20500 |
| First Posted: | February 29, 2008 Key Record Dates |
| Last Update Posted: | May 10, 2017 |
| Last Verified: | May 2017 |
Keywords provided by Genentech, Inc.:
|
SLE Lupus BELONG |
Additional relevant MeSH terms:
|
Lupus Erythematosus, Systemic Nephritis Lupus Nephritis Connective Tissue Diseases Autoimmune Diseases Immune System Diseases Kidney Diseases Urologic Diseases Glomerulonephritis Cyclophosphamide Mycophenolic Acid Immunosuppressive Agents Immunologic Factors |
Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Antibiotics, Antineoplastic Antibiotics, Antitubercular Antitubercular Agents Anti-Bacterial Agents Anti-Infective Agents Enzyme Inhibitors |